Financial Results 1st Half - FY Ending February 28, 2022 Supplementary Information

Securities ID Code: 7649, Part 1 of TSE and NSE

SUCI Holdings September 28. 2021

Contents

- 1. Financial Highlights 1st Half
 - FY Ending February 28, 2022 Consolidated -
- 2. Appendix

Financial Highlights 1st Half - FY Ending February 28, 2022 - Consolidated -

(Change in the method of presentation)

From the current fiscal year, income related to the provision of information, etc., which was included in "non-operating income", is now included in "net sales.

The relevant part of the above change is underlined in red.

Copyright SUGI Holdings Co., Ltd. All Rights Reserved.

2

Financial results highlight

Although the business environment will become more difficult, sales will continue to increase.

Net sales +4.0% 314.9 billion yen 302.7 Operating income 16.1 billion yen FY2021/2 FY2022/2 1st Half 1st Half 1st Half 1st Half

Summary of businesses

- Product sales: Reactionary decline in hygiene products, etc., whose demand expanded in the previous year.
- Dispensing: Strong double-digit growth due to aggressive opening of stores with dispensing pharmacy.

Topics

- Increasing the number of stores with dispensing facilities to expand the dispensing business.
- Control sales measures to secure gross profit margin for product sales. (Major improvement in the second quarter)
- Closed/ refurbished/ impaired some stores.

1st Half Financial Highlight - Consolidated -

	FY Ending 2 1H(March to		FY Ending 2022/2 1H(March to August)						
	Results	Ratio to Sales(%)	Results	Ratio to Sales(%)	vs. Budget	vs. Budget	Y o Y (%)		
Net Sales	(in million yen) 302,766	100.0	314,955	100.0	98.4	-5,195	104.0		
Prescription	57,284	18.9	65,291	20.7	98.3	-1,109	114.0		
Product Sales	243,384	80.4	247,522	78.6	99.0	-2,478	101.7		
Others	<u>2,098</u>	<u>0.7</u>	2,142	0.7	57.1	-1,608	102.1		
Gross Profit	<u>89,957</u>	29.7	94,125	29.9	97.9	-2,025	104.6		
Prescription	21,999	38.4	25,944	39.7	108.1	+1,944	117.9		
Product Sales	66,326	27.3	66,808	27.0	95.9	-2,891	100.7		
Others	<u>1,632</u>	<u>77.8</u>	1,373	64.0	56.0	-1,077	84.1		
SG&A Expenses	71,282	<u>23.5</u>	77,993	24.8	98.7	-1,007	109.4		
Operating Income	<u>18,675</u>	<u>6.2</u>	16,131	5.1	94.1	-1,019	86.4		
Non-Operating Income	1,530	0.5	1,478	0.5	109.5	+128	96.6		
Non-Operating Expenses	1,012	0.3	930	0.3	93.1	-70	91.9		
Ordinary Income	19,193	6.3	16,678	5.3	95.3	-822	86.9		
Extraordinary Income	0	0.0	0	0.0	-	±0	-		
Extraordinary Losses	434	0.1	1,949	0.6	389.9	+1,449	448.6		
Net Income before Income Taxes	18,758	6.2	14,729	4.7	86.6	-2,271	78.5		
Income Taxes	6,203	2.0	4,892	1.6	87.4	-708	78.9		
Net Income	12,555	4.1	9,836	3.1	86.3	-1,564	78.3		

Copyright SUGI Holdings Co.,Ltd. All Rights Reserved.

4


New store openings



Summary

- As a result of opening 50 stores and closing 6 stores, the total number of stores as of the end of May was 1,435.
- · As of the end of May, the number of stores in each area was 387 in Kanto, 516 in Chubu, 490 in Kansai, and 42 in Hokuriku.
- · As a result of the opening of new stores, the percentage of stores with dispensing facilities was 85.2% (Sugi Pharmacy business only).

The Group's existing stores sales growth rate




Summary

- Net sales (down 0.7% year on year): A reactionary deadline from the increase in corona-related demand in the previous term.
- Number of customers (down 0.3% year on year): Reactionary decline in response to the rapid increase in store visit frequency in the
 previous term.
- Sales per customer (down 0.4% year on year): The number of items purchased decreased due to a reactionary decline form the increase in demand for stay-at-home consumption in the previous term.

Copyright SUGI Holdings Co., Ltd. All Rights Reserved.

6

Changes in the number of prescriptions and price per prescription




Summary

- Dispensing Sales: Despite being affected by drug price revisions, double-digit growth continues due to an increase in the number of stores with dispensing facilities.
- · Number of prescriptions received: Increased reaction from the decline in consultations and long-term prescriptions in the previous term.
- · Prescription unit price: Reactionary decrease from unit price increase due to prolonged prescription days in the previous term.

Gross Profit Margin (Plan Comparison)

Planned difference in product sales profit margin improved



Prescription

 Despite being affected by the revision of dispensing drug prices, the trend continues to exceed the plan due to an increase in the number of stores that have acquired various additions.

Sales of goods

(Entire Group)

 Profit margin improved in the second quarter due to sales policy revision.

(By segment)

Beauty:

Improving profit margin by strengthening cooperation with business partners

Household wears and Foods:

Improving profitability by reviewing sales measures and optimizing selling prices

Copyright SUGI Holdings Co., Ltd. All Rights Reserved.

8

Sales Trend by Product Group

(%)	Compo	osition R	atio			Gross	Profit Ma	argin	Gross	Gross
	FY 2021/2 1H	FY 2022/2 1H		Sales vs. Budget	Sales Y o Y	FY 2021/2 FY 20 1H 1		022/2 H	Profit vs. Budget	Profit vs.
	Results	Budget	Results	s F	Results	Budget	Results			
Prescription	19.1	21.0	20.9	98.3	114.0	38.4	36.1	39.7	+3.6	+1.3
Product sales	80.9	79.0	79.1	99.0	101.7	27.3	27.9	27.0	-0.9	-0.3
Healthcare	20.0	19.2	19.4	99.7	101.0	38.6	39.8	38.8	-1.0	+0.2
Beauty	17.3	19.2	17.2	88.8	103.5	31.2	31.9	31.7	-0.2	+0.5
Household wares	20.3	18.4	19.6	105.6	100.8	24.2	24.1	23.8	-0.3	-0.4
Foods	23.1	22.0	22.7	101.7	101.9	17.2	17.2	16.2	-1.0	-1.0
Other	0.3	0.2	0.2	110.0	93.9	18.7	19.5	14.8	-4.7	-3.9

Continue planned control

(in million yen, %)	FY ended Fe	eb. 2021	FY ended Feb. 2022 1H						
, , , , , , , ,	Results	% of sales	Results	% of sales	% of budget	% of previous year			
Net sales	<u>302,766</u>	100.0	314,955	100.0	98.4	104.0			
Total selling expenses	3,016	1.0	3,312	1.1	78.9	109.8			
Personnel expenses	35,917	11.9	39,536	12.6	102.2	110.1			
General administrative expense	32,347	10.7	35,145	11.2	97.4	108.6			
Selling and administrative expenses	71,282	<u>23.5</u>	77,993	24.8	98.7	109.4			

Selling expense

- · Focus on cost-effective sales promotion measures.
- Promote 45th anniversary, planning with business partners.

Personnel expenses

Strengthen mid-career recruitment of qualified person such as pharmacists, etc.

General administrative expense

- Increased consumption tax payments due to increase purchases of dispensing drugs.
- Fees increase with the spread off cashless payment.
- Depreciation increases due to new store openings and DX promotion investment.

Copyright SUGI Holdings Co., Ltd. All Rights Reserved.

10

Appendix

Store Openings and Closings

Nos. of stores	FY2021/2 Full Year		FY202	22/2 1st	t Half		recast a tember			FY 202	2/2 Fu	I Year for	ecast
by region	As of the Term-End	Store Openin		Store losings	As of the Term-End	Store Openin		Store losings	Store Openin		Store osings	Change	As of the Term-End
Kanto Region	375		13	1	387		21	3		34	4	+30	405
Chubu Region	505		13	2	516		19	7		32	9	+23	528
Hokuriku Region	34		8	0	42		12	0		20	0	+20	54
Kansai Region	477		16	3	490		18	4		34	7	+27	504
Total	1,391	;	50	6	1,435	•	70	14	1:	20	20	+100	1,491
Nos. of stores	FY2021/2 Full Year		FY202	22/2 1st	Half		recast a tember		FY 2022/2 Full Year forecast				ecast
by company	As of the Term-End	Store Openings	Store Closings	Store format conversion	As of the Term-End	Store Openings	Store Closings	Store format conversion	Store Openings	Store Closings	Store format conversion	Change	As of the Term-End
Sugi Pharmacy	1,267	50	5	+2	1,314	68	14	+2	118	19	+4	+103	1,370
Japan	111	0	1	-2	108	0	0	-2	0	1	-4	-5	106
Visit Nursing Care ST	13	0	0	0	13	2	0	0	2	0	0	+2	15
Total	1,391	50	6	0	1,435	70	14	0	120	20	0	+100	1,491

Copyright SUGI Holdings Co.,Ltd. All Rights Reserved.

12

1st Half Financial Highlight - Consolidated -

	FY Ending 2 1H(March to		FY Ending 2022/2 1H(March to August)						
	Results (in million yen)	Ratio to Sales(%)	Results (in million ven)	Ratio to Sales(%)	vs. Budget (in %)	vs. Budget (in million yen)	Y o Y (%)		
Net Sales	302,766	100.0	314,955	100.0	98.4	-5,195	104.0		
Sugi Pharmacy business	269,703	<u>89.1</u>	285,258	90.6	98.7	-3,842	105.8		
Japan business	30,965	10.2	27,555	8.7	100.9	+255	89.0		
Others	<u>2,098</u>	<u>0.7</u>	2,142	0.7	57.1	-1,608	102.1		
Gross Profit	<u>89,957</u>	29.7	94,125	29.9	97.9	-2,025	104.6		
Sugi Pharmacy business	81,700	30.3	86,976	30.5	99.3	-624	106.5		
Japan business	6,625	21.4	5,777	21.0	94.7	-323	87.2		
Others	<u>1.632</u>	<u>77.8</u>	1,373	64.0	56.0	-1,077	84.1		
SG&A Expenses	71,282	<u>23.5</u>	77,993	24.8	98.7	-1,007	109.4		
Operating Income	<u>18,675</u>	<u>6.2</u>	16,131	5.1	94.1	-1,019	86.4		
Non-Operating Income	1,530	0.5	1,478	0.5	109.5	+128	96.6		
Non-Operating Expenses	1,012	0.3	930	0.3	93.1	-70	91.9		
Ordinary Income	19,193	6.3	16,678	5.3	95.3	-822	86.9		
Extraordinary Income	0	0.0	0	0.0	-	±0	-		
Extraordinary Losses	434	0.1	1,949	0.6	389.9	+1,449	448.6		
Net Income before Income Taxes	18,758	6.2	14,729	4.7	86.6	-2,271	78.5		
Income Taxes	6,203	2.0	4,892	1.6	87.4	-708	78.9		
Net Income	12,555	4.1	9,836	3.1	86.3	-1,564	78.3		

1st Half SG&A Expenses Status - Consolidated -

	FY Ending 2 (March to		FY Ending 2022/2 1H (March to August)						
	Results (in million yen)	Ratio to Sales	Results (in million yen)	Ratio to Sales	Y o Y (%)	Results (in million yen)			
Net Sales0	<u>302,766</u>	100.0	314,955	100.0	98.4	104.0			
Total Selling Expenses	3,016	1.0	3,312	1.1	78.9	109.8			
Advertising Expenses	1,730	0.6	1,973	0.6	79.0	114.1			
Premium Expenses	1,286	0.4	1,338	0.4	78.7	104.1			
Personnel Expenses	35,917	11.9	39,536	12.6	102.2	110.1			
Total Administrative Expenses	32,347	10.7	35,145	11.2	97.4	108.6			
Rent Expenses	14,687	4.9	15,953	5.1	99.1	108.6			
Depreciation Expenses	4,654	1.5	5,268	1.7	97.6	113.2			
Utilities Expenses	2,125	0.7	2,184	0.7	95.0	102.8			
Supplies Expenses	2,119	0.7	1,930	0.6	91.9	91.1			
Tax and Public Charges	2,263	0.7	2,658	0.8	102.2	117.4			
Commission Paid	3,229	1.1	3,584	1.1	102.4	111.0			
Others	3,266	1.1	3,565	1.1	87.0	109.2			
Total SG&A Expenses	71,282	<u>23.5</u>	77,993	24.8	98.7	109.4			

Copyright SUGI Holdings Co.,Ltd. All Rights Reserved.

14

Sales Trend by Product Group - Sugi -

(%)	Comp	osition I	Ratio			Gross	Profit M	Gross	Gross	
	FY 2021/2 1H	FY 2022/2 1H		Sales vs. Budget	Sales Y o Y	FY 2021/2 1H	FY 2022/2 1H		Profit vs. Budget	Profit vs.
	Results	Budget	Results			Results	Budget	Results	Duaget	YoY
Prescription	21.2	23.0	22.9	98.3	114.0	38.4	36.1	39.7	+3.6	+1.3
Healthcare	21.1	20.1	20.3	99.6	101.6	38.7	39.7	38.9	-0.8	+0.2
Beauty	18.4	20.2	18.1	88.6	103.9	31.3	32.0	31.9	-0.1	+0.6
Household wares	20.2	18.3	19.5	105.4	102.1	24.2	24.0	23.7	-0.3	-0.5
Foods	18.9	18.4	19.1	102.3	107.1	17.3	17.1	16.2	-0.9	-1.1
Other	0.1	0.1	0.1	106.9	99.2	31.1	30.3	20.6	-9.7	-10.5
Total	100.0	100.0	100.0	98.7	105.8	30.3	30.3	30.5	+0.2	+0.2

Sales Trend by Product Group - Japan -

(%)	Comp	osition F	Ratio	Sales		Gross	Profit M	argin	Gross	Gross
	FY 2021/2 1H		FY 2022/2 1H		Sales Y o Y	FY 2021/2 1H	FY 2022/2 1H		Profit vs.	Profit vs.
	Results	Budget	Results			Results	Budget Results		Budget	YoY
Healthcare	10.1	10.2	10.2	101.6	90.3	36.7	41.4	37.5	-3.9	+0.8
Beauty	7.5	8.5	7.9	93.3	93.9	28.8	29.4	28.4	-1.0	-0.4
Household wares	20.3	19.3	20.5	107.2	89.7	24.6	25.3	24.9	-0.4	+0.3
Foods	60.4	60.4	59.6	99.6	87.9	17.1	17.4	16.1	-1.3	-1.0
Other	1.7	1.6	1.7	111.8	91.2	12.1	13.0	11.4	-1.6	-0.7
Total	100.0	100.0	100.0	100.9	89.0	21.4	22.3	21.0	-1.3	-0.4


Copyright SUGI Holdings Co.,Ltd. All Rights Reserved.

16


Existing Stores Sales Growth Rate



Trends in the Number of Prescriptions and Price per Prescription



In-home Medical Care Services – As of August. 31, 2021



SUGI PHARMACY group

The forward-looking statements regarding business and other forecasts are Sugi Holdings management's decisions based on information currently available at the time the report was created, and contain risks and uncertainties.

We recommend that readers do not make their decisions solely relying on these forecasts, and readers are reminded that actual results may differ materially from these forecasts due to various circumstances beyond management's control.